Hcc202

Manufactured by American Type Culture Collection

Sourced in United States

The HCC202 is a laboratory centrifuge designed for the separation and isolation of biological samples. It features a compact and durable construction, with a maximum speed of 6,000 rpm and a rotor capacity of up to 6 x 50 mL tubes. The HCC202 is suitable for a wide range of applications in cell culture, protein purification, and molecular biology workflows.

Automatically generated - may contain errors

Lab products found in correlation

11 protocols using hcc202

Cell Line Maintenance and Reagents

Check if the same lab product or an alternative is used in the 5 most similar protocols

AU565, HCC1419, NCI-H2170, HCC202, HCC1954, NCI-N87, ZR75-1, SKOV3, ZR75-30, MDAMB175VII, CALU3, MDAMB453, MDAMB361, JIMT1, SKBR3 and HCC2218 cells were obtained from ATCC. OE19 and OE33 were obtained from ECCC; COLO-678 was obtained from DSMZ, and KYSE-410 from Sigma-Aldrich. BT-474-M3 cells (hereafter simply referred to as BT-474) were obtained from Hermes biosciences. All cell lines were maintained in RPMI supplemented with 10% FBS, penicillin, and streptomycin. GSK-1120212 and MK-2206 were purchased from Selleckchem. Recombinant human HRG-β1 (EGF domain) was from R&D Systems.

Kirouac D.C., Du J., Lahdenranta J., Onsum M.D., Nielsen U.B., Schoeberl B, & McDonagh C.F. (2016). HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B. PLoS Computational Biology, 12(4), e1004827.

+ Open protocol

+ Expand

Breast Cancer Cell Line Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human breast cancer cell lines (BT20, MCF7, HCC202, T47D, MDA-MB-453 and MDA-MB-436) were obtained from ATCC. Prior to use, cell line authentication was performed by either STR profiling at Dana-Farber Cancer Institute or by Fluidigm based fingerprinting with a panel of SNPs at The Broad Institute. Cell lines were tested for mycoplasma with the MycoAlert PLUS Mycoplasma Detection Kit (Lonza LT07) according to manufacturer’s instructions. Mouse breast tumor cell lines were established from 4 different MMTV-PyMT tumor bear mice. Mouse breast tumor cell line 7333 was implanted into wild-type littermates and once the tumor formed it was removed and used to generate the tumor cell line “MMTV”. All cells were plated at 1E4 cells/well in a 96 well plate. Cells were treated for 48 hours and CellTiter-Glo was used to assess cell viability.

Guerriero J.L., Sotayo A., Ponichtera H.E., Castrillon J.A., Pourzia A.L., Schad S., Johnson S.F., Carrasco R.D., Lazo S., Bronson R.T., Davis S.P., Lobera M., Nolan M.A, & Letai A. (2017). Class IIa HDAC inhibition reduces breast tumors and metastases via anti-tumor macrophages. Nature, 543(7645), 428-432.

+ Open protocol

+ Expand

Breast Cancer Cell Line Experimentation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Breast cancer cell lines (EFM192, BT474, HCC202, HCC1419, SUM225, and HCC1954) were a gift from Dennis Slamon, University of California Los Angeles, Los Angeles, CA; fibroblast cell lines (CCD1068, Wi38, and 3T3) were purchased from ATCC; and primary fibroblasts (AR22, CAF1, and CAF2) were derived from normal or breast cancer tissue (SI Appendix, Supplementary Methods). Cells were grown in the appropriate medium and drug dose–response assays were conducted in 96-black/clear well plates (SI Appendix, Supplementary Methods). Cyclic immunofluorescence experiments were also performed in 96-black/clear well plates, and protein lysate samples were prepared using 6-well plates and Transwell filters.

Zervantonakis I.K., Poskus M.D., Scott A.L., Selfors L.M., Lin J.R., Dillon D.A., Pathania S., Sorger P.K., Mills G.B, & Brugge J.S. (2020). Fibroblast–tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. Proceedings of the National Academy of Sciences of the United States of America, 117(28), 16500-16508.

+ Open protocol

+ Expand

Comprehensive Breast Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Breast cancer cell lines used were those frozen within 6 months of purchase from the ATCC (authenticated using STR profile analysis) and are as follows: MCF-7 (ER/PR^+ve/HER2-negative); SKBR3, HCC1954, HCC202 (ER/PR-negative/HER2^+ve); BT474 (ER/PR⁺/HER2^+ve); MDA-MB-231, HCC1806, HCC1143 (from ATCC), SUM149 and SUM159 (S. Ethier, MUSC, SC; ER/PR/HER2-negative or triple negative). These two cell lines were not authenticated independently. AOA and biochemicals were purchased from Sigma. Normal human mammary epithelial cells (HMEC) were isolated from reduction mammoplasty samples and grown in MCF10A medium (ATCC). Human breast organoids were prepared by enzymatic digestion of reduction mammoplasty tissue, collected under IRB approved protocols. Mouse tumor cell lines, MTC1 and MTC2 were established from primary mammary tumors in doxycycline-induced MMTV-rTtA-TetO-myc mice, whereas MG1 and MG2 were primary mammary glands from FVB/n litter mates.

Korangath P., Teo W.W., Sadik H., Han L., Mori N., Huijts C.M., Wildes F., Bharti S., Zhang Z., Santa-Maria C.A., Tsai H., Dang C.V., Stearns V., Bhujwalla Z.M, & Sukumar S. (2015). Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. Clinical cancer research : an official journal of the American Association for Cancer Research, 21(14), 3263-3273.

+ Open protocol

+ Expand

Comprehensive Cancer Cell Line Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

A549, BT-20, BT-474, BT-549, CAMA-1, DMS-53, DU4475, HCC38, HCC70, HCC202, HCC1143, HCC1187, HCC1395, HCC1569, HCC1806, HCC1937, HCC1954, HCC2218, HCT-116, Hs578T, Jeko-1, MCF-7, MDA-MB-134-VI, MDA-MB-157, MDA-MB-175-VII, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-436, MDA-MB-453, MDA-MB-468, MiaPaCa2, SK-BR-3, NCI-H441, SK-MEL-28, T-47D, U2OS, and ZR-75-1 were obtained from the American Type Culture Collection (ATCC) and cultured according to vendor recommendations. EFM-19 were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ) and SNU-886 were from the Korean Cell Line Bank (KCLB).
Abemaciclib, palbociclib, ribociclib, PIM447, BYL719, LY2090314, everolimus, DYRK1Bi AZ cpd 33 [32 (link)], dinaciclib, GSK2334470, abemaciclib metabolites M2 and M20 [28 (link)], and additional CDK4/6i (see Figure 2C [33 ],) were synthesized by Lilly Research Laboratories. AZD1208 (S7104) and additional palbociclib (S1579, see Supplementary Figure 1A) were purchased from Selleck Chemicals.

Litchfield L.M., Boehnke K., Brahmachary M., Mur C., Bi C., Stephens J.R., Sauder J.M., Gutiérrez S.M., McNulty A.M., Ye X.S., Wu W., Lallena M.J., Gong X., Merzoug F.F., Jansen V.M, & Buchanan S.G. (2020). Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells. Oncotarget, 11(17), 1478-1492.

+ Open protocol

+ Expand

Culturing Human Mammary and Breast Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human mammary epithelial (HMEC) cells were purchased from Lonza (Basel, Switzerland) and breast carcinoma cell lines 184A1, AU-565, CAMA-1, DU-4475, HCC-1500, HCC-1569, HCC-1806, HCC-1937, HCC-202, HCC-70, Hs578T, MCF-7, MDA-MB-157, MDA-MB-175V11, MDA-MB-468, T-47D, UACC-3199 and ZR-75-30 were purchased from American Type Culture Collection (Manassas, VA). Cells were tested negative for mycoplasma contamination and validated for species and unique DNA profile using short tandem repeat analysis by the provider or by the authors. All cell lines were cultured in RPMI Medium 1640 (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum, 1% Antibiotic-Antimycotic containing penicillin, streptomycin and Fungizone (Invitrogen, Carlsbad, CA), and 1% HEPES at 37 °C in an atmosphere containing 5% CO2.

Han Y.J., Boatman S.M., Zhang J., Du X.C., Yeh A.C., Zheng Y., Mueller J, & Olopade O.I. (2018). LncRNA BLAT1 is Upregulated in Basal-like Breast Cancer through Epigenetic Modifications. Scientific Reports, 8, 15572.

+ Open protocol

+ Expand

Comprehensive Panel of Breast Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Breast cancer cell lines derived from human female tumors were used in this study. The cell lines AU565, SKBR3, HCC1954, HCC-1569, HCC-202, HCC-2218, HCC-1419, MDA-MB-361, ZR-75-30, BT474, UACC893, and MDA-MB-453 were obtained from American Type Culture Collection (ATCC), Manassas, VA. HCC-3153 was obtained from UT-Southwestern, SUM190PT and SUM225CWN were provided by Steve Ethier at UCSF, and 21NT1, 21PT1, and 21MT1 were provided by Ruth Sager and Kornelia Polyak at the Dana-Farber Institute of Harvard, Cambridge MA. JIMT1, EFM192A, EFM192B, and EFM192C were obtained from DSMZ, Braunschweig Germany. Each cell line was genotyped to ensure accurate identity, and regularly screened for mycoplasma infection. Cell lines were maintained in their respective medium and serum concentration as recommended by originator specifications at 37°C in 5% CO2 in a humidified incubator and cultured according to ATCC recommendations.

Watson S.S., Dane M., Chin K., Tatarova Z., Liu M., Liby T., Thompson W., Smith R., Nederlof M., Bucher E., Kilburn D., Whitman M., Sudar D., Mills G.B., Heiser L.M., Jonas O., Gray J.W, & Korkola J.E. (2018). Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell systems, 6(3), 329-342.e6.

+ Open protocol

+ Expand

Comprehensive Panel of Breast Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

+ Open protocol

+ Expand

HER2-positive Breast Cancer Cell Lines

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Thirteen HER2-positive breast cancer cell lines were used in this study (Table 1). AU565, BT474, HCC1419, HCC1569, HCC1954, HCC202, MDA-MB-453, and SKBR3 were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA), and EFM-192A and JIMT1 from the German Collection of Microorganisms and Cell Cultures (DSMZ; Braunschweig, Germany). ATCC and DSMZ authenticate human cell lines by DNA typing using short tandem repeats. SUM190PT and SUM225 were provided by S Ethier from Karmanos Cancer Institute in Michigan, USA, and KPL4 by J Kurebayashi from Kawasaki Medical School in Japan. The growth media are described in Table S1. Cells were cultured for a maximum of 30 passages prior to use. ER statuses for the cell lines were obtained from the literature,15 (link)–19 (link) and only BT474 and EFM192A were ER-positive.

Jernström S., Hongisto V., Leivonen S.K., Due E.U., Tadele D.S., Edgren H., Kallioniemi O., Perälä M., Mælandsmo G.M, & Sahlberg K.K. (2017). Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast Cancer : Targets and Therapy, 9, 185-198.

+ Open protocol

+ Expand

ATRA Treatment in Breast Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell lines HCC1954, SKBR3, MCF-7, HCC202, HCC1569, and MDA-MB-453 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA), used at low (<10) passage number without further authentication or mycoplasma testing, and propagated in the appropriate medium as recommended by the manufacturer. For experiments with all-trans-retinoic acid (ATRA) (Sigma, USA, Cat#302–79-4), cells were grown in red-free media containing 10% charcoal stripped fetal bovine serum (Gibco, Cat#F6765) to remove endogenous steroids. Cells were subsequently treated for 48 hours with concentrations 0.1 and 0.5 μM of ATRA or DMSO as a negative control.

Wu V.T., Kiriazov B., Koch K.E., Gu V.W., Beck A.C., Borcherding N., Li T., Addo P., Wehrspan Z.J., Zhang W., Braun T.A., Brown B.J., Band V., Band H., Kulak M.V, & Weigel R.J. (2019). A TFAP2C Gene Signature is Predictive of Outcome in HER2-positive Breast Cancer. Molecular cancer research : MCR, 18(1), 46-56.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!